C6-Ceramide and targeted inhibition of acid ceramidase induce synergistic decreases in breast cancer cell growth

Breast Cancer Research and Treatment

Volumn 133, Issue 2, 2012, Pages 447-458

  Flowers, Margaret ^a   Fabriás, Gemma ^b   Delgado, Antonio ^b,c   Casas, Josefina ^b   Abad, Jose Luis ^b   Cabot, Myles C ^a  

^a JOHN WAYNE CANCER INSTITUTE   (United States)

^b INSTITUTE OF ADVANCED CHEMISTRY OF CATALONIA IQAC CSIC   (Spain)

^c UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Acid ceramidase; Breast cancer; Breast cancer cells; C6 ceramide; Ceramide

Indexed keywords

2 N (TETRADECANOYLAMINO) 1 (4' NITROPHENYL) 1,3 PROPANDIOL; ACID CERAMIDASE; ANTINEOPLASTIC AGENT; B 13; CASPASE 3; CASPASE 7; CERAMIDE DERIVATIVE; DM 102; HYDROLASE INHIBITOR; N (1 HYDROXYOCTADEC 3 EN 2 YL)PIVALAMIDE; N HEXANOYL DEXTRO ERYTHRO SPHINGOSINE; N OLEOYLETHANOLAMINE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BAX; PROTEIN BCL 2; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CELL MEMBRANE DEPOLARIZATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SENSITIVITY; DRUG TARGETING; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; LIPOGENESIS; MITOCHONDRIAL MEMBRANE POTENTIAL; MONOTHERAPY; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; UPREGULATION;

ACID CERAMIDASE; AMIDES; APOPTOSIS; BREAST NEOPLASMS; CELL PROLIFERATION; CELL SURVIVAL; CERAMIDES; DRUG SYNERGISM; ENZYME INHIBITORS; FATTY ACIDS, UNSATURATED; FEMALE; HUMANS; MEMBRANE POTENTIAL, MITOCHONDRIAL; REACTIVE OXYGEN SPECIES;

EID: 84863722443     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-011-1768-8     Document Type: Article

References (67)

1. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Waldron W, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Chen HS, Feuer EJ, Cronin KA, Edwards BK (eds) 2011 SEER Cancer Statistics Review 1975-2008, National Cancer Institute, Bethesda, MD. http://seer.cancer. gov/csr/1975-2008/
2. Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin 60(5):277-300
3. Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN (2007) Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol 608:1-22
4. Liu YY, Han TY, Giuliano AE, Cabot MC (2001) Ceramide glycosylation potentiates cellular multidrug resistance. FASEB J 15(3):719-730
5. Lavie Y, Cao H, Bursten SL, Giuliano AE, Cabot MC (1996) Accumulation of glucosylceramides in multidrug-resistant cancer cells. J Biol Chem 271(32):19530-19536
6. Liu YY, Han TY, Giuliano AE, Cabot MC (1999) Expression of glucosylceramide synthase, converting ceramide to glucosylcer-amide, confers adriamycin resistance in human breast cancer cells. J Biol Chem 274(2):1140-1146
7. Gouaze-Andersson V, Yu JY, Kreitenberg AJ, Bielawska A, Giuliano AE, Cabot MC (2007) Ceramide and glucosylceramide upregulate expression of the multidrug resistance gene MDR1 in cancer cells. Biochim Biophys Acta 1771(12):1407-1417
8. Ruckhaberle E, Rody A, Engels K, Gaetje R, von Minckwitz G, Schiffmann S, Grosch S, Geisslinger G, Holtrich U, Karn T, Kaufmann M (2008) Microarray analysis of altered sphingolipid metabolism reveals prognostic significance of sphingosine kinase 1 in breast cancer. Breast Cancer Res Treat 112(1):41-52
9. Watson C, Long JS, Orange C, Tannahill CL, Mallon E, McG-lynn LM, Pyne S, Pyne NJ, Edwards J (2010) High expression of sphingosine 1-phosphate receptors, S1P1 and S1P3, sphingosine kinase 1, and extracellular signal-regulated kinase-1/2 is associated with development of tamoxifen resistance in estrogen receptor-positive breast cancer patients. Am J Pathol 177(5): 2205-2215
10. Malavaud B, Pchejetski D, Mazerolles C, de Paiva GR, Calvet C, Doumerc N, Pitson S, Rischmann P, Cuvillier O (2010) Sphin-gosine kinase-1 activity and expression in human prostate cancer resection specimens. Eur J Cancer 46(18):3417-3424
11. Shirai K, Kaneshirao T, Wada M, Furuya H, Bielawski J, Hannun YA, Obeid L, Ogretmen B, Kawamori T (2011) A role of sphingosine kinase 1 in head & neck carcinogenesis. Cancer Prev Res (Phila) 4(3):454-462
12. Liu G, Zheng H, Zhang Z, Wu Z, Xiong H, Li J, Song L (2010) Overexpression of sphingosine kinase 1 is associated with salivary gland carcinoma progression and might be a novel predictive marker for adjuvant therapy. BMC Cancer 10:495
13. Seelan RS, Qian C, Yokomizo A, Bostwick DG, Smith DI, Liu W (2000) Human acid ceramidase is overexpressed but not mutated in prostate cancer. Genes Chromosom Cancer 29(2):137-146
14. Ruckhaberle E, Holtrich U, Engels K, Hanker L, Gatje R, Metzler D, Karn T, Kaufmann M, Rody A (2009) Acid ceramidase 1 expression correlates with a better prognosis in ER-positive breast cancer. Climacteric 12(6):502-513
15. Meacham WD, Antoon JW, Burow ME, Struckhoff AP, Beckman BS (2009) Sphingolipids as determinants of apoptosis and che-moresistance in the MCF-7 cell model system. Exp Biol Med (Maywood) 234(11):1253-1263
16. Holman DH, Turner LS, El-Zawahry A, Elojeimy S, Liu X, Bielawski J, Szulc ZM, Norris K, Zeidan YH, Hannun YA, Bielawska A, Norris JS (2008) Lysosomotropic acid ceramidase inhibitor induces apoptosis in prostate cancer cells. Cancer Chemother Pharmacol 61(2):231-242
17. Antoon JW, White MD, Slaughter EM, Driver JL, Khalili HS, Elliott S, Smith CD, Burow ME, Beckman BS (2011) Targeting NFkB mediated breast cancer chemoresistance through selective inhibition of sphingosine kinase-2. Cancer Biol Ther 11(7): 678-689
18. Gouaze-Andersson V, Flowers M, Karimi R, Fabrias G, Delgado A, Casas J, Cabot MC (2011) Inhibition of acid ceramidase by a 2-substituted aminoethanol amide synergistically sensitizes prostate cancer cells to N-(4-hydroxyphenyl) retinamide. Prostate 71(10):1064-1073
19. Morales A, Paris R, Villanueva A, Llacuna L, Garcia-Ruiz C, Fernandez-Checa JC (2007) Pharmacological inhibition or small interfering RNA targeting acid ceramidase sensitizes hepatoma cells to chemotherapy and reduces tumor growth in vivo. Onco-gene 26(6):905-916
20. Pchejetski D, Bohler T, Brizuela L, Sauer L, Doumerc N, Golzio M, Salunkhe V, Teissie J, Malavaud B, Waxman J, Cuvillier O (2010) FTY720 (fingolimod) sensitizes prostate cancer cells to radiotherapy by inhibition of sphingosine kinase-1. Cancer Res 70(21):8651-8661
21. Liu YY, Han TY, Yu JY, Bitterman A, Le A, Giuliano AE, Cabot MC (2004) Oligonucleotides blocking glucosylceramide synthase expression selectively reverse drug resistance in cancer cells. J Lipid Res 45(5):933-940
22. Sun Y, Zhang T, Gao P, Meng B, Gao Y, Wang X, Zhang J, Wang H, Wu X, Zheng W, Zhou G (2010) Targeting glucosyl-ceramide synthase downregulates expression of the multidrug resistance gene MDR1 and sensitizes breast carcinoma cells to anticancer drugs. Breast Cancer Res Treat 121(3):591-599
23. Selzner M, Bielawska A, Morse MA, Rudiger HA, Sindram D, Hannun YA, Clavien PA (2001) Induction of apoptotic cell death and prevention of tumor growth by ceramide analogues in met-astatic human colon cancer. Cancer Res 61(3):1233-1240
24. Stover T, Kester M (2003) Liposomal delivery enhances short-chain ceramide-induced apoptosis of breast cancer cells. J Pharmacol Exp Ther 307(2):468-475
25. Stover TC, Sharma A, Robertson GP, Kester M (2005) Systemic delivery of liposomal short-chain ceramide limits solid tumor growth in murine models of breast adenocarcinoma. Clin Cancer Res 11(9):3465-3474
26. Zolnik BS, Stern ST, Kaiser JM, Heakal Y, Clogston JD, Kester M, McNeil SE (2008) Rapid distribution of liposomal short-chain ceramide in vitro and in vivo. Drug Metab Dispos 36(8): 1709-1715
27. Antoon JW, Liu J, Gestaut MM, Burow ME, Beckman BS, Fo-roozesh M (2009) Design, synthesis, and biological activity of a family of novel ceramide analogues in chemoresistant breast cancer cells. J Med Chem 52(18):5748-5752
28. Bektas M, Jolly PS, Muller C, Eberle J, Spiegel S, Geilen CC (2005) Sphingosine kinase activity counteracts ceramide-medi-ated cell death in human melanoma cells: role of Bcl-2 expression. Oncogene 24(1):178-187
29. Mahdy AE, Cheng JC, Li J, Elojeimy S, Meacham WD, Turner LS, Bai A, Gault CR, McPherson AS, Garcia N, Beckham TH, Saad A, Bielawska A, Bielawski J, Hannun YA, Keane TE, Taha MI, Hammouda HM, Norris JS, Liu X (2009) Acid ceramidase upregulation in prostate cancer cells confers resistance to radiation: AC inhibition, a potential radiosensitizer. Mol Ther 17(3): 430-438
30. Yang F, Foekens JA, Yu J, Sieuwerts AM, Timmermans M, Klijn JG, Atkins D, Wang Y, Jiang Y (2006) Laser microdissection and microarray analysis of breast tumors reveal ER-alpha related genes and pathways. Oncogene 25(9):1413-1419
31. Elojeimy S, Liu X, McKillop JC, El-Zawahry AM, Holman DH, Cheng JY, Meacham WD, Mahdy AE, Saad AF, Turner LS, Cheng J, Day TA, Dong JY, Bielawska A, Hannun YA, Norris JS (2007) Role of acid ceramidase in resistance to FasL: therapeutic approaches based on acid ceramidase inhibitors and FasL gene therapy. Mol Ther 15(7):1259-1263
32. Maeda I, Takano T, Matsuzuka F, Maruyama T, Higashiyama T, Liu G, Kuma K, Amino N (1999) Rapid screening of specific changes in mRNA in thyroid carcinomas by sequence specific-differential display: decreased expression of acid ceramidase mRNA in malignant and benign thyroid tumors. Int J Cancer 81(5):700-704
33. Musumarra G, Barresi V, Condorelli DF, Scire S (2003) A bio-informatic approach to the identification of candidate genes for the development of new cancer diagnostics. Biol Chem 384(2): 321-327
34. Lee SC, Xu X, Lim YW, Iau P, Sukri N, Lim SE, Yap HL, Yeo WL, Tan P, Tan SH, McLeod H, Goh BC (2009) Chemotherapy-induced tumor gene expression changes in human breast cancers. Pharmacogenet Genomics 19(3):181-192
35. Hara S, Nakashima S, Kiyono T, Sawada M, Yoshimura S, Iw-ama T, Banno Y, Shinoda J, Sakai N (2004) p53-Independent ceramide formation in human glioma cells during gamma-radiation-induced apoptosis. Cell Death Differ 11(8):853-861
36. Ray PS, Gouaze-Andersson V, Giuliano AE, Cabot MC (2009) Pathologic response to neoadjuvant chemotherapy for breast cancer. Linked to enzymes that metabolize ceramide? In: Proceedings of the American Association for Cancer Research. AACR, Denver, CO
37. Juul N, Szallasi Z, Eklund AC, Li Q, Burrell RA, Gerlinger M, Valero V, Andreopoulou E, Esteva FJ, Symmans WF, Desmedt C, Haibe-Kains B, Sotiriou C, Pusztai L, Swanton C (2010) Assessment of an RNA interference screen-derived mitotic and ceramide pathway metagene as a predictor of response to neo-adjuvant paclitaxel for primary triple-negative breast cancer: a retrospective analysis of five clinical trials. Lancet Oncol 11(4):358-365
38. Bielawska A, Greenberg MS, Perry D, Jayadev S, Shayman JA, McKay C, Hannun YA (1996) (1S, 2R)-D-erythro-2-(N-myri-stoylamino)-1-phenyl-1-propanol as an inhibitor of ceramidase. J Biol Chem 271(21):12646-12654
39. Bedia C, Casas J, Garcia V, Levade T, Fabrias G (2007) Synthesis of a novel ceramide analogue and its use in a high-throughput fluorogenic assay for ceramidases. Chembiochem 8(6):642-648
40. Mao CQ, Du JZ, Sun TM, Yao YD, Zhang PZ, Song EW, Wang J (2011) A biodegradable amphiphilic and cationic triblock copolymer for the delivery of siRNA targeting the acid cerami-dase gene for cancer therapy. Biomaterials 32(11):3124-3133
41. Samsel L, Zaidel G, Drumgoole HM, Jelovac D, Drachenberg C, Rhee JG, Brodie AM, Bielawska A, Smyth MJ (2004) The cer-amide analog, B13, induces apoptosis in prostate cancer cell lines and inhibits tumor growth in prostate cancer xenografts. Prostate 58(4):382-393
42. Kanto T, Kalinski P, Hunter OC, Lotze MT, Amoscato AA (2001) Ceramide mediates tumor-induced dendritic cell apopto-sis. J Immunol 167(7):3773-3784
43. Bedia C, Canals D, Matabosch X, Harrak Y, Casas J, Llebaria A, Delgado A, Fabrias G (2008) Cytotoxicity and acid ceramidase inhibitory activity of 2-substituted aminoethanol amides. Chem Phys Lipids 156(1-2):33-40
44. Bligh EG, Dyer WJ (1959) A rapid method of total lipid extraction and purification. Can J Biochem Physiol 37(8): 911-917
45. Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzym Regul 22:27-55
46. Vandenabeele P, Vanden Berghe T, Festjens N (2006) Caspase inhibitors promote alternative cell death pathways. Sci STKE 2006(356):pe44
47. Valerie K, Yacoub A, Hagan MP, Curiel DT, Fisher PB, Grant S, Dent P (2007) Radiation-induced cell signaling: inside-out and outside-in. Mol Cancer Ther 6(3):789-801
48. Chen Y, Jungsuwadee P, Vore M, Butterfield DA, St Clair DK (2007) Collateral damage in cancer chemotherapy: oxidative stress in nontargeted tissues. Mol Interv 7(3):147-156
49. Scatena R, Bottoni P, Botta G, Martorana GE, Giardina B (2007) The role of mitochondria in pharmacotoxicology: a reevaluation of an old, newly emerging topic. Am J Physiol Cell Physiol 293(1):C12-C21
50. Le Bras M, Clement MV, Pervaiz S, Brenner C (2005) Reactive oxygen species and the mitochondrial signaling pathway of cell death. Histol Histopathol 20(1):205-219
51. Kong JY, Rabkin SW (2003) Mitochondrial effects with cera-mide-induced cardiac apoptosis are different from those of pal-mitate. Arch Biochem Biophys 412(2):196-206
52. Matsunaga T, Kotamraju S, Kalivendi SV, Dhanasekaran A, Joseph J, Kalyanaraman B (2004) Ceramide-induced intracellular oxidant formation, iron signaling, and apoptosis in endothelial cells: protective role of endogenous nitric oxide. J Biol Chem 279(27):28614-28624
53. Ogretmen B, Pettus BJ, Rossi MJ, Wood R, Usta J, Szulc Z, Bielawska A, Obeid LM, Hannun YA (2002) Biochemical mechanisms of the generation of endogenous long chain ceramide in response to exogenous short chain ceramide in the A549 human lung adenocarcinoma cell line. Role for endogenous cer-amide in mediating the action of exogenous ceramide. Biol Chem 277(15):12960-12969
54. Barth BM, Cabot MC, Kester M (2011) Ceramide-based therapeutics for the treatment of cancer. Anticancer Agents Med Chem [Epub ahead of print]
55. Hannun YA, Luberto C (2000) Ceramide in the eukaryotic stress response. Trends Cell Biol 10(2):73-80
56. Jayadev S, Liu B, Bielawska AE, Lee JY, Nazaire F, Pushkareva M, Obeid LM, Hannun YA (1995) Role for ceramide in cell cycle arrest. J Biol Chem 270(5):2047-2052
57. Fillet M, Bentires-Alj M, Deregowski V, Greimers R, Gielen J, Piette J, Bours V, Merville MP (2003) Mechanisms involved in exogenous C2-and C6-ceramide-induced cancer cell toxicity. Biochem Pharmacol 65(10):1633-1642
58. Lucci A, Han TY, Liu YY, Giuliano AE, Cabot MC (1999) Modification of ceramide metabolism increases cancer cell sensitivity to cytotoxics. Int J Oncol 15(3):541-546
59. Mehta S, Blackinton D, Omar I, Kouttab N, Myrick D, Klo-stergaard J, Wanebo H (2000) Combined cytotoxic action of paclitaxel and ceramide against the human Tu138 head and neck squamous carcinoma cell line. Cancer Chemother Pharmacol 46(2):85-92
60. Chapman JV, Gouaze-Andersson V, Messner MC, Flowers M, Karimi R, Kester M, Barth BM, Liu X, Liu YY, Giuliano AE, Cabot MC (2010) Metabolism of short-chain ceramide by human cancer cells-implications for therapeutic approaches. Biochem Pharmacol 80(3):308-315
61. Jaffrezou JP, Maestre N, de Mas-Mansat V, Bezombes C, Levade T, Laurent G (1998) Positive feedback control of neutral sphin-gomyelinase activity by ceramide. FASEB J 12(11):999-1006
62. Mancinetti A, Di Bartolomeo S, Spinedi A (2009) Long-chain ceramide produced in response to N-hexanoylsphingosine does not induce apoptosis in CHP-100 cells. Lipids 44(11):1039-1046
63. Charles AG, Han TY, Liu YY, Hansen N, Giuliano AE, Cabot MC (2001) Taxol-induced ceramide generation and apoptosis in human breast cancer cells. Cancer Chemother Pharmacol 47(5): 444-450
64. Nehra R, Riggins RB, Shajahan AN, Zwart A, Crawford AC, Clarke R (2010) BCL2 and CASP8 regulation by NF-kappaB differentially affect mitochondrial function and cell fate in anti-estrogen-sensitive and-resistant breast cancer cells. FASEB J 24(6):2040-2055
65. Engel LW, Young NA (1978) Human breast carcinoma cells in continuous culture: a review. Cancer Res 38(11 Pt 2):4327-4339
66. Lacroix M, Leclercq G (2004) Relevance of breast cancer cell lines as models for breast tumours: an update. Breast Cancer Res Treat 83(3):249-289
67. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark L, Bayani N, Coppe JP, Tong F, Speed T, Spellman PT, DeVries S, Lapuk A, Wang NJ, Kuo WL, Stilwell JL, Pinkel D, Albertson DG, Waldman FM, McCormick F, Dickson RB, Johnson MD, Lippman M, Ethier S, Gazdar A, Gray JW (2006) A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10(6):515-527